Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Arch Therapeutics Inc (ARTH)

Arch Therapeutics Inc (ARTH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 33,455
  • Shares Outstanding, K 193,045
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,550 K
  • 60-Month Beta 0.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ARTH with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 10/22/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.01
  • Number of Estimates 1
  • High Estimate -0.01
  • Low Estimate -0.01
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1460 +16.51%
on 09/03/20
0.1950 -12.77%
on 09/23/20
+0.0051 (+3.09%)
since 09/01/20
3-Month
0.1460 +16.51%
on 09/03/20
0.2270 -25.07%
on 08/07/20
+0.0101 (+6.31%)
since 07/01/20
52-Week
0.1210 +40.58%
on 10/28/19
0.2950 -42.34%
on 11/29/19
-0.0699 (-29.12%)
since 10/01/19

Most Recent Stories

More News
With FDA and EU Marketing Authorizations in Hand, 2020 and 2021 Can Be Catalyst Years for Arch Therapeutics

New York, New York--(Newsfile Corp. - September 22, 2020) -  Arch Therapeutics, Inc. (OTCQB: ARTH) has cleared significant hurdles to commercialize its AC5 Advanced Wound System and AC5 Topical Hemostat....

ARTH : 0.1721 (-0.69%)
Arch Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15 at 12 PM ET

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that Terrence W. Norchi, MD, Chief Executive...

ARTH : 0.1721 (-0.69%)
Arch Therapeutics to Present at The LD 500 Virtual Conference on Tuesday, September 1 at 1 PM ET

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that Terrence W. Norchi, MD, Chief Executive...

ARTH : 0.1721 (-0.69%)
Arch Therapeutics Novel Self-Assembling Agent, AC5-GTM, for Use in Endoscopic Procedures was Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2020 Annual Meeting

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, announces the release of research from the AC5(R) self-assembling...

ARTH : 0.1721 (-0.69%)
Arch Therapeutics Novel Self-Assembling Agent for Use in Endoscopic Procedures to be Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Virtual 2020 Annual Meeting Starting August 11, 2020

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced updated presentation information for research...

ARTH : 0.1721 (-0.69%)
Arch Therapeutics, Inc. to Present at the Virtual Investor Fireside Chat Series

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel wound care and biosurgical devices, today announced that Terrence W. Norchi, MD, Chief Executive Officer, will present...

ARTH : 0.1721 (-0.69%)
Arch Raises $1.4 Million with Convertible Note Issuance and Warrant Reprice

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel wound care and biosurgical devices, announces that it has raised $1.4M from long-term shareholders.

ARTH : 0.1721 (-0.69%)
Arch Therapeutics to Provide Corporate Update at the Virtual Summer Summit

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel wound care and biosurgical devices, will be featured as a presenting company at the Virtual Summer Summit. The conference...

ARTH : 0.1721 (-0.69%)
Do You Always Look for Earnings Beat? 5 Sectors to Play

These sectors came up with stellar earnings beat in the recent cycle. Investors can play the associated stocks that delivered an earnings surprise.

DXCM : 413.99 (+0.43%)
ORN : 2.74 (-0.36%)
SRPT : 141.46 (+0.73%)
PCH : 42.75 (+1.54%)
TNAV : 3.68 (+2.22%)
CENX : 6.98 (-1.97%)
TWLO : 255.68 (+3.48%)
AAXN : 94.56 (+4.26%)
ARTH : 0.1721 (-0.69%)
BYND : 168.32 (+1.36%)
CHWY : 58.26 (+6.26%)
Arch Therapeutics Receives CE Mark Approval for AC5(TM) Topical Hemostat in Europe

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced receipt of the CE (Conformite Europeenne) mark...

ARTH : 0.1721 (-0.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

2nd Resistance Point 0.1758
1st Resistance Point 0.1745
Last Price 0.1721
1st Support Level 0.1715
2nd Support Level 0.1698

See More

52-Week High 0.2950
Fibonacci 61.8% 0.2285
Fibonacci 50% 0.2080
Fibonacci 38.2% 0.1875
Last Price 0.1721
52-Week Low 0.1210

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar